Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews.
Efficacy
Flu
Immunogenicity
Vaccination
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
29 Aug 2023
29 Aug 2023
Historique:
received:
19
04
2023
accepted:
16
08
2023
medline:
31
8
2023
pubmed:
30
8
2023
entrez:
29
8
2023
Statut:
epublish
Résumé
Influenza infection is a highly preventable transmissible viral disease associated with mild upper respiratory symptoms and more severe conditions such as lethal pneumonia. Studies have shown that a broader spectrum influenza vaccine could reduce influenza's burden of disease in low- and middle-income countries. A considerable number of systematic reviews reported that quadrivalent influenza vaccines are considered more effective compared to trivalent vaccines, hence, there is a need for an overview in order to synthesize the current evidence pertaining to the comparison between quadrivalent and trivalent inactivated influenza vaccines. The aim was to summarize the evidence from systematic reviews that investigated the immunogenicity and safety of the Influenza's inactivated quadrivalent vaccine (QIV) compared to the trivalent vaccine (TIV), in the general population. We searched articles up to December 2022 at: Web of Science, EMBASE, MEDLINE, Cochrane Library, and SCOPUS. The search strategy was conducted following the PICO model. We included systematic reviews comparing the primary outcomes of immunogenicity (seroprotection rate and seroconversion rate) and adverse events using risk ratios. The AMSTAR 2 and ROBIS were used for quality assessments, and GRADE was used for evidence certainty assessments. We included five systematic reviews, totalling 47,740 participants. The Quadrivalent Inactivated Influenza Vaccine (QIV) exhibited enhanced immunogenicity in the context of B-lineage mismatch when compared to the Trivalent Inactivated Influenza Vaccine (TIV). While the safety profile of QIV was found to be comparable to that of TIV, the QIV showed a higher incidence of solicited local pain among children and adolescents, as well as an increased frequency of local adverse events within the adult population. Our findings suggest that the QIV provides a superior immunogenicity response compared to the TIV in all age groups evaluated, especially when a lineage mismatch occurred. The safety of QIV was considered similar to the TIV, with no serious or systemic solicited or unsolicited adverse events; tough pain at the injection site was greater for QIV. We recommend caution owing to the high risk of bias in the selection process and no protocol registration.
Sections du résumé
BACKGROUND
BACKGROUND
Influenza infection is a highly preventable transmissible viral disease associated with mild upper respiratory symptoms and more severe conditions such as lethal pneumonia. Studies have shown that a broader spectrum influenza vaccine could reduce influenza's burden of disease in low- and middle-income countries. A considerable number of systematic reviews reported that quadrivalent influenza vaccines are considered more effective compared to trivalent vaccines, hence, there is a need for an overview in order to synthesize the current evidence pertaining to the comparison between quadrivalent and trivalent inactivated influenza vaccines.
OBJECTIVE
OBJECTIVE
The aim was to summarize the evidence from systematic reviews that investigated the immunogenicity and safety of the Influenza's inactivated quadrivalent vaccine (QIV) compared to the trivalent vaccine (TIV), in the general population.
METHODS
METHODS
We searched articles up to December 2022 at: Web of Science, EMBASE, MEDLINE, Cochrane Library, and SCOPUS. The search strategy was conducted following the PICO model. We included systematic reviews comparing the primary outcomes of immunogenicity (seroprotection rate and seroconversion rate) and adverse events using risk ratios. The AMSTAR 2 and ROBIS were used for quality assessments, and GRADE was used for evidence certainty assessments.
FINDINGS
RESULTS
We included five systematic reviews, totalling 47,740 participants. The Quadrivalent Inactivated Influenza Vaccine (QIV) exhibited enhanced immunogenicity in the context of B-lineage mismatch when compared to the Trivalent Inactivated Influenza Vaccine (TIV). While the safety profile of QIV was found to be comparable to that of TIV, the QIV showed a higher incidence of solicited local pain among children and adolescents, as well as an increased frequency of local adverse events within the adult population.
CONCLUSION
CONCLUSIONS
Our findings suggest that the QIV provides a superior immunogenicity response compared to the TIV in all age groups evaluated, especially when a lineage mismatch occurred. The safety of QIV was considered similar to the TIV, with no serious or systemic solicited or unsolicited adverse events; tough pain at the injection site was greater for QIV. We recommend caution owing to the high risk of bias in the selection process and no protocol registration.
Identifiants
pubmed: 37644401
doi: 10.1186/s12879-023-08541-0
pii: 10.1186/s12879-023-08541-0
pmc: PMC10463610
doi:
Substances chimiques
Influenza Vaccines
0
Vaccines, Combined
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
563Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
Krammer F, Smith GJD, Fouchier RAM, Peiris M, Kedzierska K, Doherty PC, Palese P, Shaw ML, Treanor J, Webster RG, et al. Influenza. Nat Rev Dis Primers. 2018;4(1):3.
pubmed: 29955068
pmcid: 7097467
Kawai S, Nanri S, Ban E, Inokuchi M, Tanaka T, Tokumura M, Kimura K, Sugaya N. Influenza vaccination of schoolchildren and influenza outbreaks in a school. Clin Infect Dis. 2011;53(2):130–6.
pubmed: 21690619
Olson DR, Heffernan RT, Paladini M, Konty K, Weiss D, Mostashari F. Monitoring the impact of influenza by age: emergency department fever and respiratory complaint surveillance in New York City. PLoS Med. 2007;4(8):e247.
pubmed: 17683196
pmcid: 1939858
Perosa AH, Granato C, Bellei N. Detection of influenza B lineages from 2001 to 2013 in a tertiary hospital in the city of São Paulo, Brazil. Mem Inst Oswaldo Cruz. 2015;110(5):606–10.
pubmed: 26132429
pmcid: 4569822
Omer I, Rosenberg A, Sefty H, Pando R, Mandelboim M, Mendelson E, Keinan-Boker L, Glatman-Freedman A. Lineage-matched versus mismatched influenza B vaccine effectiveness following seasons of marginal influenza B circulation. Vaccine. 2022;40(6):880–5.
pubmed: 35016804
Orsi A, Colomba GME, Pojero F, Calamusa G, Alicino C, Trucchi C, Canepa P, Ansaldi F, Vitale F, Tramuto F. Trends of influenza B during the 2010–2016 seasons in 2 regions of north and south Italy: the impact of the vaccine mismatch on influenza immunisation strategy. Hum Vaccin Immunother. 2018;14(3):523–31.
pubmed: 28708953
Pascale JM, Franco D, Devadiga R, DeAntonio R, Dominguez-Salazar EL, Dos Santos G, Juliao P. Burden of Seasonal Influenza A and B in Panama from 2011 to 2017: an Observational Retrospective Database Study. Infect Dis Ther. 2021;10(4):2465–78.
pubmed: 34424506
pmcid: 8381717
Palekar R, Rodriguez A, Avila C, Barrera G, Barrera M, Brenes H, Bruno A, El Omeiri N, Fasce R, de Ferreira W, et al. Patterns of influenza B circulation in Latin America and the Caribbean, 2010–2017. PLoS ONE. 2019;14(8):e0219595.
pubmed: 31393886
pmcid: 6687279
Caini S, Kusznierz G, Garate VV, Wangchuk S, Thapa B, de Paula Júnior FJ, Ferreira de Almeida WA, Njouom R, Fasce RA, Bustos P, et al. The epidemiological signature of influenza B virus and its B/Victoria and B/Yamagata lineages in the 21st century. PLoS ONE. 2019;14(9):e0222381.
pubmed: 31513690
pmcid: 6742362
Puzelli S, Di Martino A, Facchini M, Fabiani C, Calzoletti L, Di Mario G, Palmieri A, Affanni P, Camilloni B, Chironna M, et al. Co-circulation of the two influenza B lineages during 13 consecutive influenza surveillance seasons in Italy, 2004–2017. BMC Infect Dis. 2019;19(1):990.
pubmed: 31752738
pmcid: 6873537
WHO. Seasonal influenza vaccines: an overview for decision-makers. License: CC BY-NC-SA 3.0 IGO. In. Geneva: World Health Organization; 2020.
Hannoun C. The evolving history of influenza viruses and influenza vaccines. Expert Rev Vaccines. 2013;12(9):1085–94.
pubmed: 24024871
Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother. 2012;8(1):81–8.
pubmed: 22252006
pmcid: 3350141
Hendriks J, Hutubessy RCW, Grohmann G, Torelli G, Friede M, Kieny MP. Quadrivalent influenza vaccines in low and middle income countries: Cost-effectiveness, affordability and availability. Vaccine. 2018;36(28):3993–7.
pubmed: 29866617
Warmath CR, Ortega-Sanchez IR, Duca LM, Porter RM, Usher MG, Bresee JS, Lafond KE, Davis WW. Comparisons in the Health and Economic assessments of using Quadrivalent Versus Trivalent Influenza Vaccines: a systematic literature review. Value Health. 2023;26(5):768–79.
pubmed: 36436790
Aoun T, Borrow R, Arkwright PD. Immunogenicity and safety of seasonal influenza vaccines in children under 3 years of age. Expert Rev Vaccines. 2023;22(1):226–42.
pubmed: 36800932
Moa AM, Chughtai AA, Muscatello DJ, Turner RM, MacIntyre CR. Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: a systematic review and meta-analysis of randomised controlled trials. Vaccine. 2016;34(35):4092–102.
pubmed: 27381642
Huang C, Fu X, Zhou Y, Mi F, Tian G, Liu X, Wu J, Ding C, Yan D, Li L, et al. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents. Vaccine. 2020;38(6):1332–44.
pubmed: 31948819
Beyer WEP, Palache AM, Boulfich M, Osterhaus A. Rationale for two influenza B lineages in seasonal vaccines: a meta-regression study on immunogenicity and controlled field trials. Vaccine. 2017;35(33):4167–76.
pubmed: 28655451
Meng ZY, Zhang JY, Zhang ZG, Luo D, Yang XM. [Immunogenicity of inacitivated quadrivalent influenza vaccine in adults aged 18–64 years: a systematic review and Meta-analysis]. Zhonghua Liu Xing Bing Xue Za Zhi. 2018;39(12):1636–41.
pubmed: 30572392
Liang Y, Jing-Xia G, Ma L, Ni L, Chaolie R, Zhou J, Guo-Yang L. Immunogenicity and safety levels of inactivated quadrivalent influenza vaccine in healthy adults via meta-analysis. Hum Vaccin Immunother. 2021;17(10):3652–61.
pubmed: 34156322
pmcid: 8437489
Sinilaite A, Gemmill I, Harrison R. Summary of the NACI Supplemental Statement on mammalian cell culture-based influenza vaccines. Can Commun Dis Rep. 2020;46(10):324–32.
pubmed: 33316000
pmcid: 7723313
de Boer PT, van Maanen BM, Damm O, Ultsch B, Dolk FCK, Crépey P, Pitman R, Wilschut JC, Postma MJ. A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Rev Pharmacoecon Outcomes Res. 2017;17(3):249–65.
pubmed: 28613092
Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018;2(2):Cd001269.
pubmed: 29388196
Wilkinson K, Wei Y, Szwajcer A, Rabbani R, Zarychanski R, Abou-Setta AM, Mahmud SM. Efficacy and safety of high-dose influenza vaccine in elderly adults: a systematic review and meta-analysis. Vaccine. 2017;35(21):2775–80.
pubmed: 28431815
Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect Dis. 2012;12(1):36–44.
pubmed: 22032844
Pollock M, Fernandes R, Becker L, Pieper D, Hartling L. Chapter V: Overviews of Reviews. In: Cochrane Handbook for Systematic Reviews of Interventions version 63 (updated February 2022) edn. Edited by Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, Welch V: Cochrane; 2022.
Gates M, Gates A, Pieper D, Fernandes RM, Tricco AC, Moher D, Brennan SE, Li T, Pollock M, Lunny C, et al. Reporting guideline for overviews of reviews of healthcare interventions: development of the PRIOR statement. BMJ. 2022;378:e070849.
pubmed: 35944924
pmcid: 9361065
Epistemonikos. database [ https://www.epistemonikos.org/en/ ].
Veritas Health Innovation. COVIDENCE: Covidence systematic review software. Melbourne, Australia: In.; 2022.
Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
pubmed: 28935701
pmcid: 5833365
Whiting P, Savović J, Higgins JP, Caldwell DM, Reeves BC, Shea B, Davies P, Kleijnen J, Churchill R. ROBIS: a new tool to assess risk of bias in systematic reviews was developed. J Clin Epidemiol. 2016;69:225–34.
pubmed: 26092286
pmcid: 4687950
Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64(4):383–94.
pubmed: 21195583
Meader N, King K, Llewellyn A, Norman G, Brown J, Rodgers M, Moe-Byrne T, Higgins JP, Sowden A, Stewart G. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Syst Rev. 2014;3:82.
pubmed: 25056145
pmcid: 4124503
Barr IG, Jelley LL. The coming era of quadrivalent human influenza vaccines: who will benefit? Drugs 2012, 72(17):2177–85.
Mckenzie L. In: Phoenix, editor. Why get a Flu Shot? Arizona: PVA Publications - a division of Paralyzed Veterans of America, Inc; 2015. pp. 22–3.
Gemmill I, Summary of the National Advisory Committee on Immunization (NACI). Statement on Seasonal Influenza Vaccine for 2015–2016. Can Commun Dis Rep. 2015;41(10):227–32.
pubmed: 29769917
pmcid: 5864413
Moore DL. Vaccine recommendations for children and youth for the 2015/2016 influenza season. Paediatr Child Health. 2015;20(7):389–94.
pubmed: 26526862
pmcid: 4614095
Caspard H, Mallory RM, Yu J, Ambrose CS. Live-attenuated Influenza Vaccine Effectiveness in Children from 2009 to 2015–2016: a systematic review and Meta-analysis. Open Forum Infect Dis. 2017;4(3):ofx111.
pubmed: 28852675
pmcid: 5569992
Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and Control of Seasonal Influenza with Vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 influenza season. MMWR Recomm Rep. 2018;67(3):1–20.
pubmed: 30141464
pmcid: 6107316
Castro Md, Leeb A, Buynder PV. Seasonal influenza immunisation for older adults in Australia: vaccine options for 2019. Volume 26. Australian Nursing and Midwifery Federation; 2019.
Gaglani M, Flannery B. Reply to Yager and Doll. Clin Infect Dis. 2020;71(12):3264–5.
pubmed: 32202294
Yager EJ, Doll MK. Towards understanding the Health and Economic Impacts of Quadrivalent and Trivalent Inactivated Vaccines against Influenza B infection: additional considerations for future cost-benefit analyses. Clin Infect Dis. 2020;71(12):3263–4.
pubmed: 32202297
Meyer J, Sibanda M, Burnett R. Vaccination against influenza saves lives – a 2021 update. Prof Nurs Today. 2021;25(1):5.
Coleman BL, Sanderson R, Haag MDM, McGovern I. Effectiveness of the MF59-adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta-analysis. Influenza Other Respir Viruses. 2021;15(6):813–23.
pubmed: 34081398
pmcid: 8542957
Sinilaite A, Young K, Harrington R. Summary of the National Advisory Committee on Immunization (NACI) Seasonal Influenza Vaccine Statement for 2021–2022. Can Commun Dis Rep. 2021;47(9):372–80.
JAMA. Influenza vaccine for 2019–2020. JAMA. 2020;323(1):84–5.
Lockwood CJ, editor. How flu shots help protect the public. Here’s what ob/gyns need to know when treating their at-risk patients. Contemporary OB/GYN 2019, 64(3):2.
NA. : Ample vaccine supply key to combating unpredictability of flu season. In.: Drug Topics; 2013.
NA. : Bracing for flu season: Steps to protect yourself right now. In.: Harvard Medical School; 2021.
Lindsey BB, Armitage EP, Kampmann B, de Silva TI. The efficacy, effectiveness, and immunogenicity of influenza vaccines in Africa: a systematic review. Lancet Infect Dis. 2019;19(4):e110–9.
pubmed: 30553695
Minozzi S, Lytras T, Gianola S, Gonzalez-Lorenzo M, Castellini G, Galli C, Cereda D, Bonovas S, Pariani E, Moja L. Comparative efficacy and safety of vaccines to prevent seasonal influenza: a systematic review and network meta-analysis. EClinicalMedicine. 2022;46:101331.
pubmed: 35360146
pmcid: 8961170
Crépey P, Redondo E, Díez-Domingo J, Ortiz de Lejarazu R, Martinón-Torres F, Gil de Miguel Á, López-Belmonte JL, Alvarez FP, Bricout H, Solozabal M. From trivalent to quadrivalent influenza vaccines: public health and economic burden for different immunization strategies in Spain. PLoS ONE. 2020;15(5):e0233526.
pubmed: 32437476
pmcid: 7241783
Eichner M, Schwehm M, Hain J, Uphoff H, Salzberger B, Knuf M, Schmidt-Ott R. 4Flu - an individual based simulation tool to study the effects of quadrivalent vaccination on seasonal influenza in Germany. BMC Infect Dis. 2014;14:365–5.
pubmed: 24993051
pmcid: 4099094
Barros EN, Cintra O, Rossetto E, Freitas L, Colindres R. Patterns of influenza B circulation in Brazil and its relevance to seasonal vaccine composition. Braz J Infect Dis. 2016;20(1):81–90.
pubmed: 26626166
Caini S, Andrade W, Badur S, Balmaseda A, Barakat A, Bella A, Bimohuen A, Brammer L, Bresee J, Bruno A, et al. Temporal patterns of Influenza A and B in Tropical and Temperate Countries: what are the Lessons for Influenza Vaccination? PLoS ONE. 2016;11(3):e0152310–0.
pubmed: 27031105
pmcid: 4816507
Regan AK, Tracey L, Gibbs R. Post-marketing surveillance of adverse events following immunization with inactivated quadrivalent and trivalent influenza vaccine in health care providers in western Australia. Vaccine. 2015;33(46):6149–51.
pubmed: 26476362
Williamson PR, Gamble C, Altman DG, Hutton JL. Outcome selection bias in meta-analysis. Stat Methods Med Res. 2005;14(5):515–24.
pubmed: 16248351
Ferreira GE, Saragiotto BT, Maher CG. Strategies to minimise concerns with selection bias in systematic reviews of interventions. Musculoskelet Sci Pract. 2021;52:102296.
pubmed: 33189656
Burdett S, Stewart LA, Tierney JF. Publication bias and meta-analyses: a practical example. Int J Technol Assess Health Care. 2003;19(1):129–34.
pubmed: 12701945
Faggion CM Jr, Wu YC, Tu YK, Wasiak J. Quality of search strategies reported in systematic reviews published in stereotactic radiosurgery. Br J Radiol. 2016;89(1062):20150878.
pubmed: 26986458
pmcid: 5258155
Hedin RJ, Umberham BA, Detweiler BN, Kollmorgen L, Vassar M. Publication Bias and Nonreporting found in majority of systematic reviews and Meta-analyses in Anesthesiology Journals. Anesth Analg. 2016;123(4):1018–25.
pubmed: 27537925
Beyer WE, Palache AM, Osterhaus AD. Comparison of Serology and Reactogenicity between Influenza Subunit Vaccines and whole virus or Split Vaccines: a review and Meta-analysis of the literature. Clin Drug Investig. 1998;15(1):1–12.
pubmed: 18370460
Kim YK, Eun BW, Kim NH, Kang EK, Lee BS, Kim DH, Lim JS. Comparison of immunogenicity and reactogenicity of split versus subunit influenza vaccine in korean children aged 6–35 months. Scand J Infect Dis. 2013;45(6):460–8.
pubmed: 23294036
Kostinov MP, Cherdantsev AP, Akhmatova NK, Praulova DA, Kostinova AM, Akhmatova EA, Demina EO. Immunogenicity and safety of subunit influenza vaccines in pregnant women. ERJ Open Res 2018, 4(2).
Hu Y, Shao M, Hu Y, Liang Q, Jia N, Chu K, Xu L, Li J, Li C, Zhu F. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China. Hum Vaccin Immunother. 2020;16(7):1691–8.
pubmed: 32347785
pmcid: 7482894
Sun W, Luo T, Liu W, Li J. Progress in the development of Universal Influenza Vaccines. Viruses 2020, 12(9).
Zhu FC, Zhou W, Pan H, Lu L, Gerez L, Nauta J, Giezeman K, de Bruijn I. Safety and immunogenicity of two subunit influenza vaccines in healthy children, adults and the elderly: a randomized controlled trial in China. Vaccine. 2008;26(35):4579–84.
pubmed: 18602729
Ye H, Jia S, Zhang Y, Li J, Zhu F. Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models. Hum Vaccin Immunother. 2020;16(11):2719–26.
pubmed: 32186950
pmcid: 7734080
Chen J, Wang J, Zhang J, Ly H. Advances in Development and Application of Influenza Vaccines. Front Immunol. 2021;12:711997.
pubmed: 34326849
pmcid: 8313855
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M, Breedveld FC, D’Amelio R, Dougados M, Kapetanovic MC, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020;79(1):39–52.
pubmed: 31413005
Banaszkiewicz A, Radzikowski A. Efficacy, effectiveness, immunogenicity–are not the same in vaccinology. World J Gastroenterol. 2013;19(41):7217–8.
pubmed: 24222970
pmcid: 3819562